Loading…
Indian pharmaceutical company selling branded formulations, with a focus on women's health and gastroenterology.
Indian pharmaceutical company selling branded formulations, with a focus on women's health and gastroenterology.
In one line: A domestic branded-generics maker.
Moat: narrow (brand). Doctor-relationship-driven branding in a few chronic therapy niches within India.
Headquarters: Ahmedabad, India · Employees: 5,153
Size Corona Remedies (CORONA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.58B, the 447th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹2,441 on 6 Nov 2026.
Performance Over six months the shares gained 40.1%, against -4.8% for the median peer and 0.0% for the India market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 17.2% over the last twelve months (peer median +1.8%); the operating margin is 18.4% (peer median 9.9%).
Valuation It trades at 63.7× forward earnings against a peer median of 23.2× (most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +21 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 13.6 points above its cost of capital (12.5% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹15.6B | ₹14.0B | ₹12.0B | ₹10.1B | ₹8.84B |
| Revenue growth | — | +17% | +18% | +15% | — |
| Gross profit | ₹7.78B | ₹6.01B | ₹5.00B | ₹3.95B | ₹3.38B |
| EBITDA | ₹3.34B | ₹2.95B | ₹2.41B | ₹1.66B | ₹1.28B |
| Net income | ₹2.07B | ₹1.85B | ₹1.49B | ₹905M | ₹849M |
| Free cash flow | n/a | ₹572M | ₹954M | -₹1.37B | ₹111M |
| Capital expenditure | n/a | ₹1.74B | ₹916M | ₹2.86B | ₹948M |
| Total debt | ₹1.15B | ₹1.65B | ₹862M | ₹1.59B | ₹280M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Corona Remedies CORONA.NS | $1.58B | +40% | +17% | 18% | 63.7× | 37.6% |
| Eris Lifesciences ERIS.NS | $1.82B | -11% | +11% | 26% | 25.7× | 24.7% |
| Mankind Pharma MANKIND.NS | $11.1B | +7% | +13% | 21% | 43.2× | 27.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CORONA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.6% | +3.6% | 4th highest of 21 |
| 6-month return | +40.1% | -4.8% | 3rd highest of 20 |
| Distance from 52-week high | -5.5% | -22.9% | 3rd highest of 21 |
| Revenue growth (TTM) | +17.2% | +1.8% | 4th highest of 20 |
| Operating margin | 18.4% | 9.9% | 5th highest of 20 |
| Forward P/E | 63.7× | 23.2× | most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 37.6% | 1.3% | 4th most demanding of 13 |
| Growth delivered (Del g) | +16.6% | +5.7% | 5th highest of 13 |
| Hurdle (Req g minus delivered) | +21.0 pp | -4.0 pp | 3rd most demanding of 13 |
| ROIC minus cost of capital | +13.6 pp | +1.2 pp | 4th highest of 20 |
| EV / EBITDA | 44.6× | 17.5× | 3rd most expensive of 7 |
| Net debt / EBITDA | 0.1× | -1.5× | 3rd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 63.7× | 37.6% | +16.6% |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 30.0× | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 29.0× | n/a | n/a |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | n/a | n/a | n/a |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 18.5× | -5.8% | +1.9% |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 27.5× | 29.6% | +29.4% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | n/a | -4.1% | +0.2% |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | n/a | 49.9% | -13.2% |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | n/a | n/a | n/a |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 27.9× | 39.6% | +359.6% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 16.2× | -4.5% | +6.8% |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 42.9× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | n/a | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% | +13.5% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 13.0× | -8.5% | +4.6% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% | -5.6% |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | n/a | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 47.5× | 6.7% | -4.3% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 18.8× | 15.3% | +19.0% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | n/a | 49.3% | +23.0% |